ライフサイエンスコーパス: dipeptidyl peptidase

1 (INS1007) is an oral reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), an enzyme responsible fo

2 tudies, CTL generated from mice deficient in dipeptidyl peptidase 1 (DPP1) were used to investigate t

3 We found that the cellular peptidases dipeptidyl peptidase 3 (DPP-3) and thimet oligopeptidase

4 Dipeptidyl peptidase 3 (DPP3) is a zinc-dependent hydrol

5 ke WTX, PALB2, and SQSTM1, we found that the dipeptidyl peptidase 3 (DPP3) protein binds KEAP1 via an

6 as a mediator of the therapeutic effects of dipeptidyl peptidase 4 (DPP-4) inhibition (vildagliptin)

7 n), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excelle

8 perglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.

9 antidiabetic incretin-based drugs, including dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-l

10 rior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have inclu

11 on-like peptide 1 receptor (GLP-1) agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, peroxisome pr

12 outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo

13 omaltase, glucose transporter 2 (GLUT2), and dipeptidyl peptidase 4 (DPP-4), as well as that of the p

14 Previous analysis of mice lacking the enzyme dipeptidyl peptidase 4 (DPP4(-/-) mice), a biomedically

15 ted proteins such as the tetraspanin CD9 and dipeptidyl peptidase 4 (DPP4) along with multiple endoso

16 due to reduced levels of the virus receptor, dipeptidyl peptidase 4 (DPP4) and higher basal levels of

17 ory syndrome coronavirus (MERS-CoV) utilizes dipeptidyl peptidase 4 (DPP4) as an entry receptor.

18 r (Gipr)-deficient mice receiving background dipeptidyl peptidase 4 (DPP4) inhibitor treatment were c

19 like peptide 1 receptor (GLP1R) agonists and dipeptidyl peptidase 4 (DPP4) inhibitors, can also reduc

20 like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase 4 (DPP4) inhibitors, with the risk

21 However, whether increased dipeptidyl peptidase 4 (DPP4) is involved in the pathoge

22 Dipeptidyl peptidase 4 (DPP4) is the receptor for cell b

23 MERS-CoV to the cell surface entry receptor dipeptidyl peptidase 4 (DPP4) occurs via S1(B) We now de

24 th Jamaican fruit bat (Artibeus jamaicensis) dipeptidyl peptidase 4 (DPP4) receptor and MERS-CoV repl

25 avirus (MERS-CoV) binds to cellular receptor dipeptidyl peptidase 4 (DPP4) via the spike (S) protein

26 Recently, the MERS-CoV receptor dipeptidyl peptidase 4 (DPP4) was identified and the spe

27 ions with the MERS-CoV cell surface receptor dipeptidyl peptidase 4 (DPP4), and evolutionary mechanis

28 receptor for MERS-CoV has been identified as dipeptidyl peptidase 4 (DPP4), the mouse DPP4 homologue

29 Taken together, our results point toward dipeptidyl peptidase 4 (DPP4)-dependent endosomal uptake

30 binding of the RBD to its cellular receptor, dipeptidyl peptidase 4 (DPP4).

31 , 4, 5, 13, and 14; sucrase isomaltase (SI); dipeptidyl peptidase 4 (Dpp4); glucose transporter type

32 Dipeptidyl peptidase 4 (DPP4, CD26) is a protease that c

33 Dipeptidyl peptidase 4 (DPP4, CD26), a type II transmemb

34 hree different epitopes in the RBD and human dipeptidyl peptidase 4 (hDPP4) interface with subnanomol

35 V after adenovirus transduction of the human dipeptidyl peptidase 4 (hDPP4) receptor and then analyze

36 omozygous (+/+) and heterozygous (+/-) human dipeptidyl peptidase 4 (hDPP4) transgenic mice to study

37 Human dipeptidyl peptidase 4 (hDPP4) was recently identified a

38 etformin (sulfonylureas, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4] inhibitors, glucagon-like

39 ike peptide 1 [GLP-1] analogue) or enhancer (dipeptidyl peptidase 4 [DPP4] inhibitor).

40 t cells were identified as a major source of dipeptidyl peptidase 4 and we also found that skin mast

41 We further show dipeptidyl peptidase 4 expression, MERS-CoV replication,

42 Previous trial results have suggested that dipeptidyl peptidase 4 inhibitor (DPP4i) use might incre

43 ficacy of two clinically used T2D drugs: the dipeptidyl peptidase 4 inhibitor linagliptin and the sul

44 rdiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patie

45 5%) while taking metformin with or without a dipeptidyl peptidase 4 inhibitor.

46 ascular safety of alogliptin, a nonselective dipeptidyl peptidase 4 inhibitor.

47 Dipeptidyl peptidase 4 inhibitors had an increased risk

48 gh biguanides, sulfonylurea, glitazones, and dipeptidyl peptidase 4 inhibitors have variable effects

49 ingestion and is critical for the actions of dipeptidyl peptidase 4 inhibitors that enhance GLP-1 lev

50 ike peptide 1 mimetics, amylin mimetics, and dipeptidyl peptidase 4 inhibitors), in addition to diet

51 nd 330) that match the human sequence in the dipeptidyl peptidase 4 receptor, making mice susceptible

52 MERS-CoV antigen; double immunostaining with dipeptidyl peptidase 4 showed colocalization in scattere

53 evaluated their efficacy and safety in human dipeptidyl peptidase 4 transgenic (hDPP4 Tg+) mice.

54 Dipeptidyl peptidase 4 was found to be expressed in mast

55 der enzymes (lactase, sucrase-isomaltase and dipeptidyl peptidase 4) and visible subepithelial and sm

56 ss spectrometry analysis revealed that DPP4 (dipeptidyl peptidase 4) was selectively expressed on the

57 corresponding oxopeptides toward cleavage by dipeptidyl peptidase 4, the principal regulator of their

58 lmonary expression of the MERS-CoV receptor, dipeptidyl peptidase 4, was similar in marmosets and mac

59 ns, the neural cell adhesion molecule L1 and dipeptidyl peptidase 4, were further studied.

60 of incretin mimetic drugs and inhibitors of dipeptidyl peptidase 4, which degrades GLP-1.

61 Trials of inhibitors of dipeptidyl peptidase 4, which enhance the effect of endo

62 romal cell-derived factor-1-degrading enzyme dipeptidyl peptidase 4.

63 tors expressing the human host-cell receptor dipeptidyl peptidase 4.

64 itute or an inhibitor of the serine protease dipeptidyl peptidase 4.

65 cludens-1, mucins-1 and -2, antigen A33, and dipeptidyl peptidase 4.

66 stasis: neural cell adhesion molecule L1 and dipeptidyl peptidase 4.

67 glucosyltransferase); butyrylcholinesterase; dipeptidyl-peptidase 4 (CD26, adenosine deaminase comple

68 Dipeptidyl-peptidase 4 (DPP-4) inhibitors are increasing

69 CoV spike (S) glycoprotein to sialosides and dipeptidyl-peptidase 4 (the attachment and entry recepto

70 Acarbose, the dipeptidyl-peptidase 4-inhibitor sitagliptin, the glucag

71 Dipeptidyl peptidase-4 (CD26, DPP4) inhibitors are the m

72 Dipeptidyl peptidase-4 (DDP4) inhibitors target the enzy

73 te effects of treatment with vildagliptin on dipeptidyl peptidase-4 (DPP-4) activity, glucagon-like p

74 nes are terminated via enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4) and through renal clearan

75 Fibroblast activation protein (FAP) and dipeptidyl peptidase-4 (DPP-4) are highly homologous ser

76 nguish FAP from other prolyl peptidases like dipeptidyl peptidase-4 (DPP-4) have not been developed.

77 (GLP-1) receptor agonists and inhibitors of dipeptidyl peptidase-4 (DPP-4) have shown pleiotropic ef

78 in this subgroup who also had baseline serum dipeptidyl peptidase-4 (DPP-4) higher than the populatio

79 od, crossover study in 24 patients with T2D, dipeptidyl peptidase-4 (DPP-4) inhibition and its glucos

80 bese mice (ob/ob), 45h was as effective as a dipeptidyl peptidase-4 (DPP-4) inhibitor at reducing pea

81 Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use

82 Linagliptin is a dipeptidyl Peptidase-4 (DPP-4) inhibitor that inhibits t

83 Dipeptidyl peptidase-4 (DPP-4) inhibitors have pleotropi

84 In this regard, dipeptidyl peptidase-4 (DPP-4) inhibitors have recently

85 acological levels of GLP-1 activity, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors increase conce

86 1 (GLP-1) secretion, on glucose lowering by dipeptidyl peptidase-4 (DPP-4) inhibitors is unclear.

87 Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent degrad

88 Recent studies concluded that dipeptidyl peptidase-4 (DPP-4) inhibitors provide glycem

89 ike peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors represent 2 di

90 etformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-gl

91 italized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating unce

92 mpared with an active comparator drug class, dipeptidyl peptidase-4 (DPP-4) inhibitors, in patients w

93 GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit

94 bute to the mechanism by which inhibitors of dipeptidyl peptidase-4 (DPP-4) lower postprandial glucos

95 on of enzymatic degradation by inhibition of dipeptidyl peptidase-4 (DPP-4) promotes glycemic reducti

96 ears to prevent apoptosis, and inhibition of dipeptidyl peptidase-4 (DPP-4), which cleaves GLP-1, is

97 GLP-1 and GLP-2 are both cleaved by dipeptidyl peptidase-4 (DPP-4); hence, inhibition of DPP

98 Aminopeptidases, such as dipeptidyl peptidase-4 (DPP-4, CD26), are potent therape

99 ulated genes, we identified the exopeptidase dipeptidyl peptidase-4 (DPP4) as a critical glucocortico

100 nfect both humans and dromedary camels using dipeptidyl peptidase-4 (DPP4) as its receptor.

101 Given the role of Dipeptidyl Peptidase-4 (DPP4) in glucose homeostasis, we

102 icyte interactions, as well as the effect of dipeptidyl peptidase-4 (DPP4) inhibitor on CD in endothe

103 The incretin-based therapies, dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon-li

104 viously disclosed azolopyrimidine containing dipeptidyl peptidase-4 (DPP4) inhibitors led us to focus

105 Dipeptidyl peptidase-4 (DPP4) inhibitors used for the tr

106 Dipeptidyl peptidase-4 (DPP4) modulates inflammation by

107 Dipeptidyl peptidase-4 (DPP4) was recently identified as

108 Cells marked by dipeptidyl peptidase-4 (DPP4)/CD26 expression are highly

109 Blocking dipeptidyl peptidase-4 activity resulted in decreased po

110 gon like peptide-1 levels and a reduction in dipeptidyl peptidase-4 activity.

111 antidiabetic agents such as sulfonylureas or dipeptidyl peptidase-4 antagonists, which promote glucos

112 We investigated whether chronic dipeptidyl peptidase-4 inhibition by sitagliptin protect

113 At 30 minutes recovery, dipeptidyl peptidase-4 inhibition mitigated the postisch

114 d-line glucose-lowering medication-including dipeptidyl peptidase-4 inhibitor (DPP4i), insulin, or th

115 dy, we compared the safety and efficacy of a dipeptidyl peptidase-4 inhibitor (sitagliptin) plus basa

116 analyses comparing empagliflozin versus the dipeptidyl peptidase-4 inhibitor class, and comparing so

117 ium-glucose cotransporter-2 inhibitor versus dipeptidyl peptidase-4 inhibitor classes also produced c

118 controlled cardiovascular safety trials, the dipeptidyl peptidase-4 inhibitor linagliptin demonstrate

119 analyses of HF and related outcomes with the dipeptidyl peptidase-4 inhibitor linagliptin versus plac

120 inhibitor dapagliflozin with and without the dipeptidyl peptidase-4 inhibitor saxagliptin, and the ef

121 adverse events for those associated with the dipeptidyl peptidase-4 inhibitor sitagliptin and the glu

122 The dipeptidyl peptidase-4 inhibitor sitagliptin, an antidia

123 The addition of dipeptidyl peptidase-4 inhibitor therapy with sitaglipti

124 creasing thiazolidinedione use and increased dipeptidyl peptidase-4 inhibitor use over time (P<0.001)

125 f newer antihyperglycemic medications in the dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-

126 o assess the effectiveness of linagliptin, a dipeptidyl peptidase-4 inhibitor, in elderly patients wi

127 gonist, versus maximum approved doses of the dipeptidyl peptidase-4 inhibitor, sitagliptin, or the th

128 itiating empagliflozin versus sitagliptin, a dipeptidyl peptidase-4 inhibitor.

129 CI 1.15-1.76; six trials), intermediate with dipeptidyl peptidase-4 inhibitors (1.25, 1.08-1.45; two

130 rsus 4.9%), sulfonylurea (8.7% versus 6.9%), dipeptidyl peptidase-4 inhibitors (10.6% versus 7.5%), S

131 n compared with thiazolidinediones (TZDs) or dipeptidyl peptidase-4 inhibitors (DPP-4is) as a third a

132 ndings from preclinical studies suggest that dipeptidyl peptidase-4 inhibitors and proton-pump inhibi

133 ials supporting the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and some glucagon-like

134 lucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used for

135 There are also concerns that dipeptidyl peptidase-4 inhibitors could cause cancer, gi

136 ncretin system, GLP-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors for 26 +/- 8 months be

137 Some but not all dipeptidyl peptidase-4 inhibitors have been associated w

138 1 analogs, alpha-glucosidase inhibitors, and dipeptidyl peptidase-4 inhibitors were associated with w

139 diones were used in 6.6% of HF patients, and dipeptidyl peptidase-4 inhibitors were used in 5.1%, wit

140 n-like peptide [GLP]-1 receptor agonists and dipeptidyl peptidase-4 inhibitors) have proven efficacy

141 t for 6-12 months and once-weekly tablets of dipeptidyl peptidase-4 inhibitors.

142 s continued taking metformin with or without dipeptidyl peptidase-4 inhibitors.

143 the glucagon-like peptide-1 mimetics and the dipeptidyl peptidase-4 inhibitors.

144 essing enzyme corin and BNP-degrading enzyme dipeptidyl peptidase-4 were reduced in HF versus normal,

145 We identified a single protein, CD26 (dipeptidyl peptidase-4).

146 otentially by producing excessive amounts of Dipeptidyl peptidase-4, a protease that is a target of d

147 s augmented by pharmacological inhibition of dipeptidyl peptidase-4.

148 cluding CD103(+) and CD11b(hi) cDCs, express dipeptidyl peptidase-4/CD26.

149 inally, combination of DGAT1 inhibition with dipeptidyl-peptidase-4 (DPP-4) inhibition led to further

150 Fasting adipocytokines and dipeptidyl-peptidase-4 concentrations were measured.

151 Dipeptidyl-peptidase-4 levels increased after surgery (P

152 nel subunit Kv4.2 with its auxiliary subunit dipeptidyl peptidase 6 (DPP6), and thereby modulates neu

153 racting proteins (KChIPs) and transmembrane, dipeptidyl peptidase 6 and 10 (DPP6/10) accessory subuni

154 The dipeptidyl-peptidase 6 gene has been associated with a n

155 We report that dipeptidyl-peptidase 6 interacts with a filopodia-associ

156 Dipeptidyl-peptidase 6 is an auxiliary subunit of Kv4-me

157 We find that the hippocampal neurons lacking dipeptidyl-peptidase 6 show a sparser dendritic branchin

158 dipeptidyl-peptidase 6 therefore has an unexpected but i

159 we employ knockdown and genetic deletion of dipeptidyl-peptidase 6 to reveal its importance for the

160 including dipeptidyl peptidase IV (DPP IV), dipeptidyl peptidase 8 (DPP8), fibroblast activation pro

161 Here we identified the cytosolic dipeptidyl peptidase 9 (DPP9) as a SUMO1 interacting pro

162 3.98 x 10(-12)) within the gene that encodes dipeptidyl peptidase 9 (DPP9); and on chromosome 21q22.1

163 es inflammasome activation in the context of dipeptidyl peptidase 9 inhibition and could thereby incr

164 ilization, but decreases NLRP1 activation on dipeptidyl peptidase 9 inhibition.

165 lose FAP homologues dipeptidyl peptidase IV, dipeptidyl peptidase 9, and prolyl oligopeptidase.

166 demonstrate that M1184V increases binding to dipeptidyl peptidase 9, which can account for its inhibi

167 se in gelatinase activity, whereas levels of dipeptidyl peptidase activity remained unchanged.

168 Both proteases display dipeptidyl peptidase activity, but FAP alone has endopep

169 types of EDTA-resistant protease activities: dipeptidyl peptidase and a 170-kDa gelatinase activity.

170 Dipeptidyl peptidases (DP) 8 and 9 are homologous, cytop

171 The dipeptidyl peptidase (DPP) 4 family includes four enzyme

172 The intracellular peptidases dipeptidyl peptidase (DPP) 8 and DPP9 are involved in mu

173 Dipeptidyl peptidase (DPP)-4 inhibition is a glucose-low

174 The binding kinetics and thermodynamics of dipeptidyl peptidase (DPP)-4 inhibitors (gliptins) were

175 Dipeptidyl peptidase (DPP)-IV inhibitory peptides were p

176 l modification of chemokines mediated by the dipeptidyl peptidase DPP4 (CD26) has been shown to negat

177 administration of an inhibitor of the enzyme dipeptidyl-peptidase (DPP4i), which prevents the cleavag

178 Like the closely related dipeptidyl peptidase DPPIV, the extracellular domain of

179 Dipeptidyl peptidases (DPPs) are proteolytic enzymes tha

180 ncy and high selectivity against the related dipeptidyl peptidases (DPPs) DPPIV, DPP9, DPPII, and pro

181 demonstrate that this effect is prevented by dipeptidyl peptidases (DPPs), which cleave NPY to its sh

182 ors that are selective for FAP over both the dipeptidyl peptidases (DPPs), with which it shares exope

183 f dipeptide production processes mediated by dipeptidyl-peptidases (DPPs) should be beneficial for th

184 rectly inhibits the activity of MMP20, KLK4, dipeptidyl peptidase I (DPPI) (an in vitro activator of

185 Dipeptidyl peptidase I (DPPI) is a cysteine aminopeptida

186 Dipeptidyl peptidase I (DPPI) is a cysteine protease req

187 Dipeptidyl peptidase I (DPPI) is a lysosomal cysteine pr

188 e injected TxA into ileal loops in PAR(2) or dipeptidyl peptidase I (DPPI) knockout mice or in wild-t

189 In this study, we show that the absence of dipeptidyl peptidase I (DPPI), a lysosomal cysteine prot

190 Cathepsin C, or dipeptidyl peptidase I, is a lysosomal cysteine protease

191 n inactivating mutation in the gene encoding dipeptidyl peptidase I, resulting in neutrophils lacking

192 aring features like propeptide processing by dipeptidyl peptidase I, storage, and release as an activ

193 ial of alpha-amylase, alpha-glucosidase, and dipeptidyl peptidase III (DPP III) enzyme activities.

194 Dipeptidyl peptidase III (DPP III) is one of the most im

195 glucagon-like peptide 1 (GLP1) mimetics and dipeptidyl peptidase inhibitors that enhance GLP1 recept

196 6)PAL) and GIP(Lys(37)PAL) were resistant to dipeptidyl peptidase IV (DPP IV) degradation.

197 Dipeptidyl peptidase IV (DPP IV) is a ubiquitous membran

198 Binding of plasminogen type II (Pg 2) to dipeptidyl peptidase IV (DPP IV) on the surface of the h

199 method to a variety of proteases, including dipeptidyl peptidase IV (DPP IV), dipeptidyl peptidase 8

200 ained lactam aminoboronic acid inhibitors of dipeptidyl peptidase IV (DPP IV; E.C. 3.4.14.5).

201 e synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of typ

202 novel aminopiperidine-fused imidazopyridine dipeptidyl peptidase IV (DPP-4) inhibitor 1 has been dev

203 ered as potent, selective, and orally active dipeptidyl peptidase IV (DPP-4) inhibitors by extensive

204 les are rapidly inactivated by the action of dipeptidyl peptidase IV (DPP-4) which limits their use a

205 Dipeptidyl peptidase IV (DPP-IV) belongs to a family of

206 Dipeptidyl peptidase IV (DPP-IV) degrades the incretin h

207 e synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of ty

208 e synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of ty

209 agon-like peptide-1 (GLP-1) degrading enzyme dipeptidyl peptidase IV (DPP-IV) have been shown to be e

210 Xanthine oxidase (XO) and dipeptidyl peptidase IV (DPP-IV) inhibition by amino aci

211 acid linked l-cis-4,5-methanoprolinenitrile dipeptidyl peptidase IV (DPP-IV) inhibitors led to the i

212 ad angiotensin-I-converting enzyme (ACE) and dipeptidyl peptidase IV (DPP-IV) inhibitory activities,

213 tent angiotensin converting enzyme (ACE) and dipeptidyl peptidase IV (DPP-IV) inhibitory and oxygen r

214 Nine novel dipeptidyl peptidase IV (DPP-IV) inhibitory peptides (FL

215 ts (DOE) was used to optimise the release of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides dur

216 of 72 dietary proteins to act as a source of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides.

217 Camel milk proteins contain dipeptidyl peptidase IV (DPP-IV) inhibitory peptides.

218 as no significant effect of pH regulation on dipeptidyl peptidase IV (DPP-IV) properties.

219 These peptides are known to act as preferred dipeptidyl peptidase IV (DPP-IV) substrates.

220 l screening was performed against the target dipeptidyl peptidase IV (DPP-IV) to identify good chemic

221 HSA), other components, such as the protease dipeptidyl peptidase IV (DPP-IV), possibly contribute to

222 Dipeptidyl peptidase IV (DPP-IV; E.C. 3.4.14.5), a serin

223 Dipeptidyl peptidase IV (DPP4) deactivates glucose-regul

224 Dipeptidyl peptidase IV (DPP4) inhibitors are emerging a

225 Dipeptidyl peptidase IV (DPP4/CD26) and seprase/fibrobla

226 Dipeptidyl peptidase IV (DPPIV) activity was quantified

227 epatocytes can give rise to SHPCs, rats with dipeptidyl peptidase IV (DPPIV) chimeric livers, which h

228 expression of CD26, especially its intrinsic dipeptidyl peptidase IV (DPPIV) enzyme activity, results

229 ine (C5-Pro-Pro) analogues was discovered as dipeptidyl peptidase IV (DPPIV) inhibitors as a potentia

230 Dipeptidyl peptidase IV (DPPIV) is a serine protease wit

231 as evaluated by injecting cell isolates from dipeptidyl peptidase IV (DPPIV) positive (DPPIV+) Fische

232 Dipeptidyl peptidase IV (DPPIV), a cell surface serine p

233 ddresses the hypothesis that the activity of dipeptidyl peptidase IV (DPPIV), an enzyme that inactiva

234 FAPalpha exhibits a dipeptidyl peptidase IV (DPPIV)-like fold, featuring an

235 g the protocol of injecting hepatocytes from dipeptidyl peptidase IV (DPPIV)-positive donors into ret

236 ffects of HIR on engraftment of transplanted dipeptidyl peptidase IV (DPPIV)-positive hepatocytes in

237 rotein (FAP) is a serine protease related to dipeptidyl peptidase IV (DPPIV).

238 ed structure of AprA has similarity to human dipeptidyl peptidase IV (DPPIV).

239 y inhibition of the closely related protease dipeptidyl peptidase IV (DPPIV).

240 proteins after enzymatic digestion, against dipeptidyl peptidase IV (DPPIV); an enzyme known to deac

241 Wild-type (dipeptidyl peptidase IV [DPPIV(+)]) embryonic day (ED) 1

242 hepatocyte colonies with strong canalicular dipeptidyl peptidase IV activity.

243 tivities, among them primarily inhibition of dipeptidyl peptidase IV and angiotensin-converting enzym

244 both analogues were completely resistant to dipeptidyl peptidase IV degradation.

245 assays based on F344 recipient rats lacking dipeptidyl peptidase IV enzyme activity to identify tran

246 ibited APCE with a K(i) of 54 microM but not dipeptidyl peptidase IV even at 2 mM.

247 vivo, but this effect was only detected with dipeptidyl peptidase IV inhibition, while mucosal respon

248 ulocyte-colony stimulating factor (G-CSF), a dipeptidyl peptidase IV inhibitor (DPP-4i), and a proton

249 in medicinal chemistry applications such as dipeptidyl peptidase IV inhibitors.

250 The highest dipeptidyl peptidase IV inhibitory activity was obtained

251 tal liver cells were transplanted into adult dipeptidyl peptidase IV knockout mice and differentiated

252 One week post-MMC treatment, dipeptidyl peptidase IV negative host rats were given a

253 vivo and mature into hepatocytes expressing dipeptidyl peptidase IV or fumarylacetoacetate hydrolase

254 ntained large clusters of sinusoids lined by dipeptidyl peptidase IV positive endothelial cells coexp

255 newborn, or adult total liver isolates from dipeptidyl peptidase IV positive rats.

256 ent on degradation by neutral endopeptidase, dipeptidyl peptidase IV, and aminopeptidase P.

257 ts but does not inhibit close FAP homologues dipeptidyl peptidase IV, dipeptidyl peptidase 9, and pro

258 Three groups of mutant F344 dipeptidyl peptidase IV-deficient (DPPIV(-)) rats were r

259 , we used transplanted cells as reporters in dipeptidyl peptidase IV-deficient mice.

260 hepatocytes were transplanted into syngeneic dipeptidyl peptidase IV-deficient rats followed by histo

261 F344 rat hepatocytes with or without DAR in dipeptidyl peptidase IV-deficient rats.

262 ter transplanting syngeneic hepatocytes into dipeptidyl peptidase IV-deficient rats.

263 t and proliferation of transplanted cells in dipeptidyl peptidase IV-deficient rats.

264 hepatocytes were transplanted into syngeneic dipeptidyl peptidase IV-deficient rats.

265 d Fischer 344 rat hepatocytes into syngeneic dipeptidyl peptidase IV-deficient rats.

266 r repopulation by histochemical staining for dipeptidyl peptidase IV.

267 n, expression of sucrase isomaltase (SI) and dipeptidyl-peptidase IV (DPP-IV), two well known intesti

268 ow cytometry and histochemical estimation of dipeptidyl-peptidase IV enzyme activity of donor cells i

269 in juvenile and senescent rats deficient in dipeptidyl-peptidase IV.

270 -glucosidase (37.8%), alpha-amylase (35.6%), dipeptidyl peptidase-IV (34.4%), reactive oxygen species

271 uggest a variety of bioactivities, including dipeptidyl peptidase-IV (DPP-IV) and angiotensin convert

272 wever, its rapid degradation by enzymes like dipeptidyl peptidase-IV (DPP-IV) and neutral endopeptida

273 f GLP-1 is short due to rapid degradation by dipeptidyl peptidase-IV (DPP-IV) and renal clearance.

274 P-1 is short because of rapid degradation by dipeptidyl peptidase-IV (DPP-IV) and renal clearance.

275 Dipeptidyl peptidase-IV (DPP-IV) inhibitors are poised t

276 Dipeptidyl peptidase-IV (DPP-IV) is a serine protease in

277 P-1, due to its resistance to degradation by dipeptidyl peptidase-IV (DPP-IV).

278 ate or propionate increased DBS, enhanced by dipeptidyl peptidase-IV (DPPIV) inhibition, at the same

279 s are a good source of natural inhibitors of dipeptidyl peptidase-IV and prolyl endopeptidase and cou

280 The dipeptidyl peptidase-IV inhibitor saxagliptin (Onglyza)

281 tivities and clinical variants, for example, dipeptidyl peptidase-IV inhibitor-associated noninflamma

282 d 1-beta-fructofuranosyl nystose) are potent dipeptidyl peptidase-IV inhibitors as well as peroxisome

283 ction of several serine proteases, including dipeptidyl peptidase-IV, neutrophil elastase, matrix met

284 Dipeptidyl-peptidase-IV-deficient female rats received B

285 yeast of Blastomyces dermatitidis elaborates dipeptidyl-peptidase IVA (DppIVA), a close mimic of the

286 Protein biochemistry has identified dipeptidyl peptidase-like protein 6 (DPP6) as an auxilia

287 Dipeptidyl peptidase-like protein 6 (DPP6) is an auxilia

288 , the Ca(2+) binding proteins KChIPs and the dipeptidyl peptidase-like proteins (DPPLs) DPP6 (also kn

289 +) channel-interacting proteins (KChIPs) and dipeptidyl peptidase-like proteins (DPPLs).

290 ) channel-interacting proteins (KChIPs), and dipeptidyl peptidase-like proteins (DPPLs).

291 cell-base experiments with Kv4.2 and several dipeptidyl-peptidase-like protein-6 (DPPX) plasmid const

292 metabotropic glutamate receptor 5 (mGluR5), dipeptidyl-peptidase-like protein-6 (DPPX), and gamma-am

293 mined the putative novel contribution of the dipeptidyl-peptidase-like protein-6 DPP6-S to the gamma

294 Kv channel-interacting proteins (KChIPs) and dipeptidyl-peptidase-like proteins (DPLs: DPP6 or DPPX,

295 hannel interacting proteins (KChIPs) and the dipeptidyl-peptidase-like proteins (DPPLs) DPPX (DPP6) a

296 ulating the biophysical properties of Kv4.2: dipeptidyl-peptidase-like type II transmembrane proteins

297 Conversely, DPP-4 Asp663 stabilizes dipeptidyl peptidase substrate binding and permits tight

298 marked TSS energy for both endopeptidase and dipeptidyl peptidase substrates, and structural modeling

299 Although endopeptidase, dipeptidyl peptidase, tripeptidyl peptidase, and acylami

300 Dipeptidyl peptidase type IV (DppIV) enzymes are broadly